While not all trials present the expected results [59], intranasal insulin in the postprandial state was shown to reduce appetite, increase signaling in the amygdala, and, in some cases, increase the desire to eat only low-caloric food [59,60], making it a potential future target for obesity treatment and prevention. The gene discussed is INS; the disease is obesity disorder.